摘要
目的:探讨腹腔镜中间型卵巢肿瘤细胞减灭术治疗晚期卵巢癌的临床效果。方法:选取收治的22例晚期卵巢癌患者为研究组,开展新辅助化疗加腹腔镜中间型卵巢肿瘤细胞减灭术加术后辅助化疗。另选取晚期卵巢癌患者作为对照组,实施肿瘤细胞减灭术联合术后辅助化疗。比较两组临床疗效、手术满意度、手术时间、术中失血量以及术后住院时间、术后并发症发生情况、术后1~3年生存率。结果:研究组近期疗效总有效率高于对照组(P<0.05);研究组手术满意度(74.51%)高于对照组(51.49%),而手术时间及术中失血量分别均低于对照组,差异均有统计学意义(均P<0.05);两组术后肠梗阻、切口渗液、直肠穿孔以及切口感染发生率比较差异均无统计学意义(均P>0.05);两组术后1~3年生存率比较差异无统计学意义(P>0.05)。结论:腹腔镜中间型卵巢肿瘤细胞减灭术治疗晚期卵巢癌的临床效果较佳,且有效缩短手术时间,减少术中失血量,不会增加并发症及死亡风险。
Objective To study the clinical effect of laparoscopic intermediate ovarian tumor cell reduction in the treatment of advanced ovarian cancer.Method Twenty-two patients with advanced ovarian cancer admitted to our hospital were included in the study as study group,and neoadjuvant chemotherapy+laparoscopic intermediate ovarian tumor cell reduction+postoperative adjuvant chemotherapy were performed.In addition,the patients with advanced ovarian cancer were selected as the control group,and tumor cell reduction combined with postoperative adjuvant chemotherapy was performed.The clinical efficacy,surgical satisfaction,surgical time,intraoperative blood loss,postoperative length of hospital stay,postoperative complications and postoperative 1-3 year survival rate were compared between the two groups.Results The total effective rate of study group was higher than control group(P<0.05).The surgical satisfaction of study group was 74.51%,higher than 51.49%of control group,while the operative time and intraoperative blood loss were lower than control group(all P<0.05).There were no significant differences in the incidence of postoperative intestinal obstruction,incision effusion,rectal perforation and incision infection between the two groups(all P>0.05).There was no significant difference in 1-3 year survival rate between the two groups(all P>0.05).Conclusion Laparoscopic intermediate ovarian tumor cell reduction has a good clinical effect in the treatment of advanced ovarian cancer,and can effectively shorten the operation time,reduce intraoperative blood loss,without increasing the risk of complications and death.
作者
黄利珊
杨海坤
魏伟锋
曾维红
HUANG Li-shan;YANG Hai-kun;WEI Wei-feng(Meizhou people's Hospital,Meizhou 514043,China)
出处
《吉林医学》
CAS
2022年第7期1781-1784,共4页
Jilin Medical Journal
基金
2019年度梅州市社会发展科技计划项目[项目编号:2019B022]。
关键词
卵巢癌
腹腔镜中间型卵巢肿瘤细胞减灭术
新辅助化疗
临床疗效
并发症
Ovarian cancer
Laparoscopic intermediate ovarian tumor cell reduction
Neoadjuvant chemotherapy
Clinical efficacy
Complications
